Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

News in Brief

Stephen Hahn Confirmed as FDA Commissioner

DOI: 10.1158/2159-8290.CD-NB2019-137 Published February 2020
  • Article
  • Info & Metrics
  • PDF
Loading

The U.S. Senate confirmed Stephen Hahn, MD, as the next FDA commissioner in December by a vote of 72–18. The Senate Committee on Health, Education, Labor, and Pensions recommended Hahn's confirmation following a November hearing during which senators probed his thinking on several issues, notably how the agency would respond to the burgeoning use of electronic cigarettes (e-cigarettes), also known as vaping, and to calls for greater regulation of tobacco in general.


Embedded Image

Stephen Hahn, MD

A radiation oncologist, Hahn, 59, most recently served as chief medical executive at The University of Texas MD Anderson Cancer Center in Houston. Before moving there in 2014, he worked at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia for 18 years and served as its chair of radiation oncology from 2005 to 2014.

President Donald Trump announced his nomination of Hahn for the post on November 1. Although Norman “Ned” Sharpless, MD, who now heads the NCI, served as interim commissioner for much of 2019, the agency has not had a permanent leader since Scott Gottlieb, MD, left the job last April.

Jennifer Grandis, MD, of the University of California, San Francisco, backed Hahn's appointment, saying that it's beneficial to have a physician-scientist in the post who understands research and patient needs. In addition, Hahn “has the political skills to navigate an already politicized environment” in Washington, she noted.

Benjamin Toll, PhD, of the Medical University of South Carolina in Charleston, agreed that Hahn is an excellent choice. “If he can do a good job at MD Anderson, I'm confident he can do a good job at FDA.”

Prior to the vote of the full Senate, Erika Sward, assistant vice president of national advocacy for the American Lung Association, said the organization does not take stances on nominees, but she wanted a commissioner who would mandate FDA reviews of e-cigarettes sooner rather than later. The next FDA head needs to “advocate within the administration for what will protect kids, not what will protect tobacco companies,” she said.

At the hearing, Hahn acknowledged that “it requires bold action to keep these [devices] out of the hands of kids.” Subsequently, the FDA released final guidance on January 2 underscoring that manufacturers of “new” tobacco products on the market since 2016 need to submit applications for review by May 12, and that the agency will prioritize enforcement of the regulations. Further, the agency has mandated the removal of all flavored tobacco products from the market, including flavored e-cigarette cartridges, except for those with menthol and tobacco flavors. Flavorings have made e-cigarettes particularly attractive to youths.

Hahn will also oversee the implementation of the FDA's Technology Modernization Action Plan, which was released in September. The plan will guide the agency as it updates and rethinks technologies such as data systems so that new discoveries can benefit the public more quickly. “We are committed to ensuring that our mechanisms for collecting, reviewing, and analyzing data are equally as sophisticated as the scientific advances that we are reviewing,” said Hahn.

Elaine Mardis, PhD, of Nationwide Children's Hospital in Columbus, OH, and president of the American Association for Cancer Research, expressed confidence in Hahn. He “understands the challenges that patients face every day,” she said, “and [he] also knows firsthand the importance of utilizing science-based evidence to evaluate the safety and efficacy of new therapies and devices.” –Mitch Leslie

Notes

For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2020 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 10 (2)
February 2020
Volume 10, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Stephen Hahn Confirmed as FDA Commissioner
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Stephen Hahn Confirmed as FDA Commissioner
Cancer Discov February 1 2020 (10) (2) 167-168; DOI: 10.1158/2159-8290.CD-NB2019-137

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Stephen Hahn Confirmed as FDA Commissioner
Cancer Discov February 1 2020 (10) (2) 167-168; DOI: 10.1158/2159-8290.CD-NB2019-137
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Agios Exits Oncology
  • Congress Approves Increase in Cancer Funding
  • Tasmanian Devil Facial Tumor Disease Turns Endemic
Show more News in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement